Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial

OBJECTIVE: The immunomodulatory effects of the CCR5-antagonist maraviroc might be beneficial in patients with a suboptimal immunological response, but results of different cART (combination antiretroviral therapy) intensification studies are conflicting. Therefore, we performed a 48-week placebo-con...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:PLoS One
Asıl Yazarlar: van Lelyveld, Steven F. L., Drylewicz, Julia, Krikke, Maaike, Veel, Ellen M., Otto, Sigrid A., Richter, Clemens, Soetekouw, Robin, Prins, Jan M., Brinkman, Kees, Mulder, Jan Willem, Kroon, Frank, Middel, Ananja, Symons, Jori, Wensing, Annemarie M. J., Nijhuis, Monique, Borghans, José A. M., Tesselaar, Kiki, Hoepelman, Andy I. M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Public Library of Science 2015
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4514679/
https://ncbi.nlm.nih.gov/pubmed/26208341
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0132430
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller